Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Response to consensus statement
- Gerard Boehm, MD, MPH,
- Judith A. Racoosin, MD, MPH,
- Thomas P. Laughren, MD and
- Russell Katz, MD
- Division of Neuropharmacological Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland
- Address correspondence to Dr. Judith A. Racoosin, 5600 Fishers Ln., HFD-120, Rockville, MD 20857. E-mail: racoosinj{at}cder.fda.gov
In the February 2004 issue of Diabetes Care, the American Diabetes Association (ADA) published a summary of their conclusions drawn from the Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes (1). Although the ADA ranked the diabetes risk for second-generation antipsychotics (SGAs), the U.S. Food and Drug Administration’s Division of Neuropharmacological Drug Products (DNDP) does not believe that the evidence currently available allows such a ranking.
The ADA concluded that aripiprazole and ziprasidone have no effect on the risk of diabetes. The ADA notes that because these two drugs have not been included in epidemiological studies, this conclusion is solely based on data from clinical trials that did not …
